Melipramin

Imipramine, the active ingredient in Melipramin, is a tricyclic antidepressant presented as an oral tablet for oral use. It is prescribed for major depressive disorder, panic disorder, and nocturnal enuresis in adults and selected pediatric cases.

GNH USA supplies Melipramin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides batch‑tested product with full regulatory documentation.

Imipramine is used in the management of several psychiatric and urological conditions. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Panic disorder: reduces frequency and severity of panic attacks. - Nocturnal enuresis: decreases nighttime urinary episodes in children.

Imipramine may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Dry mouth: reduced salivary flow. - Constipation: slowed bowel movements. - Drowsiness: increased sleepiness. - Blurred vision: temporary visual changes.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heartbeat, especially in overdose. - Seizures: risk of convulsive episodes. - Severe hypotension: sudden drop in blood pressure.

When prescribing imipramine, clinicians should consider several safety measures to minimize risks. - Assess cardiac history: evaluate for pre‑existing heart disease or conduction abnormalities. - Monitor blood pressure: watch for orthostatic changes, especially at treatment initiation. - Review concomitant CNS depressants: avoid additive sedation with alcohol or benzodiazepines. - Caution in elderly: increased susceptibility to anticholinergic effects and falls. - Pregnancy and lactation: weigh potential risks and benefits; use only if clearly indicated. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Imipramine can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome; must be discontinued at least 14 days prior. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase imipramine plasma levels, raising toxicity risk. - Anticholinergic drugs: additive anticholinergic burden leading to severe dry mouth, urinary retention, or constipation.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs, triptans): monitor for serotonin syndrome symptoms. - Diuretics: may enhance orthostatic hypotension. - Antihypertensives: possible additive blood pressure lowering effect.